Experimental organ injury
3Experimental research; clinical benefit is not established.
What does it do?
EDL tripeptide marketed as a bioregulator. Available primary experiments described by the reference concern kidney endpoints, not established human liver/GI benefit.
Approved & studied uses
Community uses Reported, unvalidated
Kidney injury
16Rat cisplatin, gentamicin and ischemia–reperfusion models.
Renal aging
16Cell-senescence and aged-rat diuresis findings.
Liver/GI marketing
16Reference identifies weak secondary-source support; not demonstrated clinical protection.
Reasons people report using it; these do not establish benefit.16
Evidence limits
View research →No verified human liver or kidney treatment trial establishes efficacy or safety.3
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Kidney-to-liver inference
Rat kidney-injury findings cannot establish liver treatment in people.3
Investigational; this profile does not establish an approved use.
Length3 amino acids
Molecular weight · Da375.37 Da
Formula, sequence notation & identity
E–D–LGlu–Asp–Leu (EDL)
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pep-Pedia identity details
3 amino acids (tripeptide) · 375.37 Da
Glu-Asp-Leu (H-E-D-L-OH)Reference description; checked chemical identity above takes precedence when available.16
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life15 min15
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 1.25 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Zamorskii et al. 2017 Bull Exp Biol Med (PMID 28744634)
Source’s reported peak time: 2 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Scope of evidence
No verified human liver or kidney treatment trial establishes efficacy or safety.3
Community poll 1 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1 response” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Russian supplement availability is not pharmaceutical approval. Class-level toxicity assumptions and source compatibility labels do not establish safety.
No verified human protocol or quantified community report included.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- Days to 2 weeks in rat AKI models
- Break
- No published evidence-based interval
Reported timing
No measured Cmax / Tmax / half-life published
Oral
- Use period
- Per BAFS product label
- Break
- Per BAFS product label
Reported timing
No published human PK; follow the BAFS product label
Side effects & safety
Kidney-to-liver inference
Rat kidney-injury findings cannot establish liver treatment in people.
3Unmeasured human effects
The verified experiment does not define a human dose, clearance rate or adverse-event frequency.
3Unknown human safety
No dedicated safety/PK study; oral absorption, interactions and special populations uncharacterized.
Stop symptoms
Allergy, altered/painful urination, persistent injection reactions or unexpected systemic effects.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Livagen
Caution reportedDifferent peptide/tissue evidence; marketing confusion.16
Reference report · Pep-Pedia label: Use CautionCisplatin/gentamicin/NSAIDs
Caution reportedAnimal nephroprotection is not clinical protection.16
Reference report · Pep-Pedia label: Monitor CombinationDiuretics
Caution reportedPossible additive diuresis; untested in humans.16
Reference report · Pep-Pedia label: Monitor CombinationPinealon
Unverified pairingUntested pairing.16
Reference report · Pep-Pedia label: CompatibleCartalax
Unverified pairingUntested pairing.16
Reference report · Pep-Pedia label: CompatibleImmunosuppressants
Unverified pairingNo interaction data.16
Reference report · Evidence context: UnknownHepatotoxic medicines
Unverified pairingNot proven protective.16
Reference report · Evidence context: UnknownOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.4
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.4
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.4
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia distinguishes supplement capsules from third-party dry research material and states that no human dose is established.
- Solvents mentioned
- 0.9% sterile sodium chloride / Bacteriostatic water
- Reported parameters
- Dry and prepared material: reported 2–8°C. · Reported prepared-solution interval: 7–10 days.
The source describes gentle mixing and avoiding vigorous shaking.
Oral
The source describes Russian supplement capsules.
- Form
- Source describes a prepared product
- Reported parameters
- Dose, course, storage and shelf life depend on the product label.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite lyophilized powderReported appearanceSealed vial with batch and expiryReported appearanceClear reconstituted solutionReported variationVerify sequence is EDL (Glu-Asp-Leu)Reported variationDisambiguate from other Russian products named OvagenReported concernCloudy, yellow, or particulate solution
16Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
16Lyophilized: 2-8°C. Reconstituted: 2-8°C, use within 7-10 days.
Per BAFS product label
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
PreclinicalSource context
Russian supplement availability is not pharmaceutical approval. Class-level toxicity assumptions and source compatibility labels do not establish safety.
Compound identity & other names
Ovagen is commonly identified as the EDL tripeptide. Verified original research concerns experimental renal injury in rats; claims of human liver regeneration are not demonstrated by those experiments.
Other names: EDL
Investigational; this profile does not establish an approved use.
How it may work
Proposed DNA binding and renal senescence/MMP-14 signaling; cell entry and clinical relevance remain unclear.16
Experimental rat kidney injury
EDL improved kidney-function and oxidative-stress markers in rat injury models. A human dosing regimen was not reported in the abstract.
3Research areas and evidence gaps
Experimental organ injury. Experimental research; clinical benefit is not established.3
- No verified human liver or kidney treatment trial establishes efficacy or safety.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.4
No numeric human-use schedule was captured in the inspected Pep-Pedia protocol section.
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.
- Checked
- 2026-10-12
- Search
- Ovagen peptide study
- Catalog
- Pep-Pedia ↗ · 12 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different GenesisAbstract checked
AI-PREPARED SUMMARY
EDL improved renal injury and oxidative-stress measures in rats with gentamicin nephropathy or ischemia/reperfusion.
Pep-Pedia bibliography · Checked 2026-10-12
2Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different GenesisAbstract checked
AI-PREPARED SUMMARY
EDL improved renal injury and oxidative-stress measures in rats with gentamicin nephropathy or ischemia/reperfusion.
Pep-Pedia bibliography · Checked 2026-10-12
3Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different GenesisAbstract checked
AI-PREPARED SUMMARY
EDL improved renal injury and oxidative-stress measures in rats with gentamicin nephropathy or ischemia/reperfusion.
Experimental rat kidney injury
EDL improved kidney-function and oxidative-stress markers in rat injury models. A human dosing regimen was not reported in the abstract.
Additional research · Checked 2026-10-12
4Pep-Pedia: OvagenCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
5Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh (2015). Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. Bulletin of Experimental Biology and Medicine, 159(6), 736-739.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: EDL improved urinary and filtration measures in cisplatin-injured rats; this is kidney-model evidence, not proof of a human liver benefit.
Reported population / model
Rat
Reported study details
Cisplatin model · Functional renal endpoints
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Khavinson VKh, Tarnovskaya SI, Lin'kova NS, Polyakova VO, Durnova AO, Nichik TE, Kvetnoi IM, Dyakonov MM, Yakutseni PP (2014). Tripeptides slow down aging process in renal cell culture. Advances in Gerontology, 27(2), 265-270.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Aged rat kidney cultures showed more proliferation, lower p16/p21/p53 and higher SIRT6 after EDL.
Reported population / model
Rat
Reported study details
Primary kidney cell culture · Senescence markers
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Khavinson VKh, Lin'kova NS, Polyakova VO, Durnova AO, Nichik TE, Kvetnoi IM (2014). Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging. Bulletin of Experimental Biology and Medicine, 157(6), 731-734.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: EDL increased MMP-14 expression in kidney cultures; the kidney extract and AED had distinct cell-renewal responses.
Reported population / model
Rat
Reported study details
Kidney cell culture · Polypeptide complex + AED + EDL
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Khavinson VKh, Lin'kova NS, Tarnovskaya SI (2016). Short Peptides Regulate Gene Expression. Bulletin of Experimental Biology and Medicine, 162(1), 288-292.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Biophysical work associated EDL/AEDL with a CTCC DNA motif; cell entry and downstream clinical relevance remain uncertain.
Reported population / model
Biophysical
Reported study details
19 short Khavinson peptides
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Peptide Bioregulators in Aged Rat Kidneys (Adv Gerontol, 2018)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Aged rats had a reported 1.2–1.4-fold rise in urine output and antioxidant-enzyme changes; clinical kidney protection was not established.
Reported population / model
Rat
Reported study details
Aged · Multiple peptides including EDL
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules, 26(22), 7053.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh (2015). Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. Bulletin of Experimental Biology and Medicine, 159(6), 736-739.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
12Khavinson VKh, Lin'kova NS, Polyakova VO, Durnova AO, Nichik TE, Kvetnoi IM (2014). Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging. Bulletin of Experimental Biology and Medicine, 157(6), 731-734.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
13Khavinson VKh, Lin'kova NS, Tarnovskaya SI (2016). Short Peptides Regulate Gene Expression. Bulletin of Experimental Biology and Medicine, 162(1), 288-292.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
14Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules, 26(22), 7053.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
15Pep-Pedia: Ovagen — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 15 min and a peak time of 2 min. Stated attribution: Zamorskii et al. 2017 Bull Exp Biol Med (PMID 28744634). This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
16Pep-Pedia: Ovagen — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12